Document is current
Any future updates will be listed below
-
Authors
Stewart, Stuart
Kalra, Philip A.
Blakeman, Tom
Kontopantelis, Evangelos
Cranmer-Gordon, Howard
Sinha, Smeeta
-
Funding
Funding for this research was provided by:
Kidney Research UK (AHPF_001_20220705)
- License Information
-
More Information
Article History
Received: 1 June 2024
Accepted: 5 August 2024
First Online: 15 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: SSt receives funding from Kidney Research UK; award number AHPF_001_20220705. SSi received honoraria from AZ, Boehringer, Menarini, Novartis, GSK, CSL Vifor and Bayer. PK received grant funding from CSL Vifor and Astellas, consulting fees from Astra Zeneca, Vifor, Unicyte and UCB, honoraria from Astra Zeneca, Pfizer, Pharmacosmos, Medice, GSK, Bayer and CSL Vifor. EK – None to declare. TB – No financial conflicts of interest; NHS England Think Kidneys Programme Board Member (2014–17); Royal College of General Practitioners’ AKI Clinical Champion (2017–20); NHSE Renal Services Transformation Programme Post-AKI care Lead (2021–23); Specialist Committee Member for NICE AKI Quality Standard (QS76) (2022–23); Kidney Disease Improving Global Outcomes (KDIGO) AKI Guideline Work Group (2023-To date). HCG none to declare.
